sounds very good to me!cheersbirdseyePrima BioMed on global...

sounds very good to me!
cheers
birdseye

Prima BioMed on global expansion trail, says Lucy Turnbull
• BY:GAVIN LOWER
• From:Dow Jones Newswires
• May 25, 2012 4:27PM

THE dual-listed Australian cancer therapy company Prima BioMed has no immediate plans to delist from the Australian stock exchange, despite recently appointing a new chief executive who will be based in San Francisco, chairwoman Lucy Turnbull said.

Questions have been raised recently about the depth of Australia's investment pool for biotechnology companies after Biota Holdings last month revealed plans to delist its Australian shares and merge with Nasdaq-listed Nabi Biopharmaceuticals to help it access US capital markets.

In 2011, over $US10 billion ($10.25bn) was raised by development-stage life science companies in the US, compared to about $600 million in Australia, Biota said.
Prima is also listed on the Nasdaq, and its securities began trading only last month.

"Our shareholder base is very, very dominantly Australian," Ms Turnbull told Dow Jones Newswires in an interview last week, but added "who knows what may happen in five or 10 years time".
Ms Turnbull said Prima was an Australian company, and highlighted its close links with the Peter MacCallum Cancer Centre in Melbourne and the fact that its cancer vaccine technology was developed by the Burnet Institute, also in Melbourne.

"It's got a strong Australian connection. It's also developing a global footprint, but we are very much an Australian company," she said.

This week the company said chief operating officer Matthew Lehman would take over as chief executive from Martin Rogers on September 1. Mr Lehman will be based in San Francisco, where Prima said it plans to concentrate its longer-term operational expansion.

Prima said the management change was intended to progress trials and regulatory development of its CVac therapy, a vaccine to help improve survival rates of women with ovarian cancer.

"The clinical trials are directed towards seeing whether it's a successful maintenance therapy for people with ovarian cancer so that their life expectancy increases and that their quality of life increases," Ms Turnbull said.
Late stage trials for CVac are currently under way with some results from its CAN-003 trial, which is testing the effectiveness of the therapy in patients whose ovarian cancer is in remission, expected later this year or early next year, she said. Recruitment for an 800-patient trial is expected to be completed by the next quarter.

http://www.theaustralian.com.au/business/companies/prima-biomed-on-global-expansion-trail-says-lucy-turnbull/story-fn91v9q3-1226367187109